TABLE 1.
DASS‐42 anxiety and depression scores at baseline time point in two magnesium supplemented groups and in the overall ITT population
| Parameter | Magnesium + vitamin B6 (N = 132) | Magnesium (N = 132) | Total (N = 264) |
|---|---|---|---|
| DASS‐42 anxiety | n (%) | n (%) | n (%) |
| Normal (scale 0–7) | 25 (18.9) | 26 (19.7) | 51 (19.3) |
| Mild (8–9) | 7 (5.3) | 10 (7.6) | 17 (6.4) |
| Moderate (10–14) | 31 (23.5) | 27 (20.5) | 58 (22.0) |
| Severe (15–19) | 25 (18.9) | 24 (18.2) | 49 (18.6) |
| Extremely severe (20–42) | 44 (33.3) | 45 (34.1) | 89 (33.7) |
| DASS‐42 depression | n (%) | n (%) | n (%) |
| Normal (scale 0–9) | 47 (35.6) | 43 (32.6) | 90 (34.1) |
| Mild (10–13) | 18 (13.6) | 20 (15.2) | 38 (14.4) |
| Moderate (14–20) | 33 (25.0) | 33 (25.0) | 66 (25.0) |
| Severe (21–27) | 16 (12.1) | 23 (17.4) | 39 (14.8) |
| Extremely severe (28–42) | 18 (13.6) | 13 (9.8) | 31 (11.7) |
Note: No significant differences (p < 0.05) were identified between the magnesium + vitamin B6 group and magnesium group (Chi square test). DASS‐42 at baseline was included in the analysis models to account for any disparities observed at baseline.
Abbreviations: DASS‐42, Depression Anxiety Stress Scales; ITT, intent‐to‐treat.